Adisseo(SH:600299) Chang Jiang Shang Bao·2025-12-19 00:21Core Viewpoint - Andy Su has successfully completed a large-scale private placement, raising a total of 3.98 billion shares and 3 billion yuan, with significant interest from institutional investors [1][3][4]. Fundraising Details - The private placement involved issuing 398 million shares at a price of 7.54 yuan per share, raising a total of 3 billion yuan, with a net amount of 2.984 billion yuan after expenses [3][4]. - The top recipient of the shares was Caitong Fund, which received 694 million yuan, becoming the second-largest shareholder with a 2.99% stake [1][6]. Use of Proceeds - The funds raised will be allocated to functional product projects, special product projects, sustainable development projects, and to supplement working capital [2][8]. - Specifically, 1.743 billion yuan (46.3% of total funds) will be invested in a solid methionine project, while 257 million yuan will go towards special product projects [8]. Market Performance - As of December 18, Andy Su's stock price reached 8.93 yuan, resulting in a paper profit of 553 million yuan for the 20 investors within a day [2][7]. Financial Performance - For the first three quarters of 2025, Andy Su reported revenue of 12.931 billion yuan, a year-on-year increase of 13.67%, while net profit decreased by 1.29% to 990 million yuan [10]. - The company has faced challenges such as declining vitamin prices and increased distribution costs due to tariffs, but is implementing strategies to mitigate these impacts [10]. Research and Development - Andy Su is enhancing its R&D efforts, with planned expenditures increasing from 301 million yuan in 2020 to 442 million yuan in 2024, and 282 million yuan spent in the first three quarters of 2025 [11].